“…Calcium influx triggers insulin release from b cells (Ashcroft, 2006;Nichols, 2006). Moreover, genetic mutations of genes encoding K ATP subunits cause diseases, such as neonatal diabetes, hyperinsulinism, DEND syndrome, and Cantú syndrome (Nichols, 2006;Quan et al, 2011), manifesting that K ATP channels are important therapeutic targets. K ATP channel inhibitors, such as sulfonylureas, are widely used for treating type II diabetes, while K ATP channel activators, such as potassium channel openers, are used for treating hyperinsulinism and have shown great promise for myoprotection (Flagg et al, 2010).…”